QRxPharma Ltd
QRxPharma Limited (ASX: QRX; OTCQX: QRXPY) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) disorders. The Company’s lead products comprise a patented combination of existing drugs, with a well-defined path to regulatory approval and sales. QRxPharma’s lead drug compound, MoxDuo™ IR (Q8003IR), began Phase III clinical trials in November 2007. The Company’s preclinical and clinical pipeline includes other technologies in the fields of neurodegenerative disease and venomics.
QRxPharma inks agreement with TSX-listed Patheon
QRxPharma Limited (ASX: QRX, OTCQX: QRXPY) has added further value for shareholders, inking an agreement with Toronto listed Patheon Inc. (TSX: PTI) to manufacture clinical supplies of QRxPharma’s Dual-Opioid™ formulation (MoxDuo™CR).
Patheon is a leading contract drug developer and manufacturing for the pharmaceutical and biotechnology industries.
Patheon has a market capitalisation of C$180 million and revenues of US$717 million.
MoxDuo™CR is designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic).
The most advanced pain treatment product, MoxDuo™IR (immediate release formulation), is now in Phase 3 trials and scheduled for New Drug Application (NDA) filing with the US Food and Drug Administration in 2010.
“The Patheon relationship represents a major step forward for QRxPharma that rounds out our platform of MoxDuo™ products,” said Dr. John Holaday managing director.
“We are targeting a twice daily dosage with MoxDuo™ CR, and we anticipate our initial Phase 1 studies will begin this year to evaluate the pharmacokinetic profile of this patented formulation, Holaday said.”
QRxPharma’s formulation of MoxDuo™CR is anticipated to complete clinical trials in 2012.
The company believes MoxDuo™CR will deliver clinical benefits similar to those clinically demonstrated with MoxDuo™IR – fewer side effects and superior pain relief.
Other QRxPharma Ltd news
-
06/01/10 Australian Ethical Investments lodges substantial shareholder notice with QRxPharma
-
10/12/09 QRxPharma to launch acute pain drug in 2011
-
13/11/09 QRxPharma requests suspension pending capital raisings
-
24/09/09 QrxPharma inks alliance with China biopharmaceutical company
-
25/08/09 QrxPharma's MoxDuo™ IR drug demonstrates fewer side effects than Percocet in trial
-
24/07/09 QRXPharma commences Phase 2 study to increase pain relief for hip replacement surgery patients
Investors interested in QRxPharma Ltd recently viewed
-
Access Pharmaceuticals (OTCBB: .ACCP)
-
Alliance Pharma plc (AIM: APH)
-
Amphion Innovations (LON: AMP)
-
Asterand (LSE: ATD)
-
Biocompatibles (LSE: BII)
-
BioNeutral Group (OTCBB: .BONU)
-
Bionomics Limited (ASX: .BNO)
-
Circadian Technologies Limited (ASX: .CIR)
-
CogState Limited (ASX: .CGS)
-
Eco Animal Health Group Plc (AIM: EAH)
-
Epistem (AIM: EHP)
-
ImmuPharma Plc (AIM: IMM)
-
Lipoxen Plc (AIM: LPX)
-
Oxford Nutrascience (AIM: ONG)
-
Renovo Group Plc (LSE: RNVO)
-
Sinclair Pharma plc (AIM: SPH)
-
Starpharma Holdings (ASX: .SPL)
-
Stirling Products Limited (ASX: .STI)









